Clinical trials: Omalizumab
Healthy
To Compare the PK and Safety of Omalizumab (CT-P39, EU-approved Xolair, and US-licensed Xolair) in Healthy Subjects
A Phase 1, Randomized, Double-blind, Three-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics and Safety of Three Formulations of Omalizumab (CT-P39, EU-approved Xolair, and US-licensed Xolair) in Healthy…
- Trial name
- NCT04018313
- Testing
- CT-P39, EU-approved Xolair, US-licensed Xolair
- Where
- 2 sites in Australia
- Volunteers
- 176 people, healthy volunteers welcome
- Sponsor
- Celltrion
ALLERGIC ASTHMA
A Description of Inflammatory Cell Types In Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE Therapy
The researcher proposes to assess levels of sputum inflammatory markers (eosinophils, eosinophil cationic protein (ECP), neutrophils IL-8) before and while on anti-IgE therapy in a pediatric population of moderate to severe…
- Trial name
- NCT00283504
- Testing
- ANTI-IGE THERAPY (XOLAIR)
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Children's Hospital of The King's Daughters
Cat Allergy
The Effects of Omalizumab (Anti-IgE) on the Late-phase Response to Nasal Allergen Challenge
This research is being done to study the effects of the drug omalizumab (Xolair) in people with cat allergies. The investigators will use omalizumab to study changes in the cells in the nose, cells in the blood and cells in the…
- Trial name
- NCT01003301
- Testing
- Omalizumab
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University